RuiYi is a La Jolla, California-based global therapeutic innovation provider focused on discovering and developing monoclonal antibodies against G protein-coupled receptors (GPCRs). Its core pipeline includes RYI-008, a novel anti-IL-6 monoclonal antibody for rheumatoid arthritis and cancer, and RYI-018, a monoclonal antibody to cannabinoid receptor 1 (CB-1). RYI-018 was identified via the company’s iCAPS platform and targets a commercially validated but previously intractable drug target. The company plans to file an IND and initiate clinical trials in multiple countries in 2015 for RYI-008 and to advance RYI-018 into preclinical studies. Financially, RuiYi closed a $4M debt financing from Silicon Valley Bank and previously completed a $15M Series B in March 2014. Discovery efforts and its research facility are located in the Zhangjiang Hi‑Tech Park in Pudong, Shanghai, China. RuiYi develops innovative monoclonal antibodies directed at previously untargeted G protein–coupled receptors (GPCRs) to address global therapeutic needs. Its pipeline includes a lead anti‑IL‑6 antibody, RYI‑008, and discovery programs against GPCRs such as cannabinoid receptor 1 (CB‑1). The company intends to use new funding to advance RYI‑008 and to discover and develop additional therapeutic mAbs targeting GPCRs. RuiYi is led by Paul A. Grayson (President & CEO), Erik Karrer, Ph.D. (Chief Scientific Officer), and Brian Campion, Ph.D. (VP of Business Development). It maintains a research facility at Zhangjiang Hi‑Tech Park in Pudong, Shanghai and is based in La Jolla, California. The company raised $15m in a Series B to support continued development and discovery work.

Total raised

$19M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Jun 2014